Previous close | 98.40 |
Open | 97.61 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 97.29 - 97.61 |
52-week range | 97.29 - 97.61 |
Volume | |
Avg. volume | N/A |
Market cap | 9.575B |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | 21.42 |
EPS (TTM) | 4.54 |
Earnings date | 02 Feb 2022 - 07 Feb 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
With me as usual are Kevin Gorman, our chief executive officer; Matt Abernethy, our chief financial officer; Eiry Roberts, our chief medical officer; Eric Benevich, our chief commercial officer; and Kyle Gano, our chief business development and strategy officer. Before we get going, I'll remind everyone that during today's call, we will be making forward-looking statements.
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...